BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9696489)

  • 1. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus.
    Lee JH; von Wagner M; Roth WK; Teuber G; Sarrazin C; Zeuzem S
    J Hepatol; 1998 Jul; 29(1):29-35. PubMed ID: 9696489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamics of serum hepatitis C virus load and quasispecies complexity during antiviral therapy in patients with chronic hepatitis C.
    Grahovac B; Bingulac-Popovic J; Vucelic B; Hrstic I; Ostojic R; Drazic V; Balija M; Grgicevic D
    J Clin Virol; 2001 Jan; 20(1-2):85-9. PubMed ID: 11163588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypervariable region 1 of hepatitis C virus genome and response to interferon therapy.
    Grahovac B; Bingulac-Popović J; Vucelić B; Hrstić I; Ostojić R; Drazić V; Balija M; Grgicević D
    Clin Chem Lab Med; 2000 Sep; 38(9):905-10. PubMed ID: 11097348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral effect of human recombinant interleukin-12 in patients infected with hepatitis C virus.
    Lee JH; Teuber G; von Wagner M; Roth WK; Zeuzem S
    J Med Virol; 2000 Mar; 60(3):264-8. PubMed ID: 10630957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiviral effect of ribavirin in early non-responders to interferon monotherapy assessed by kinetics of hepatitis C virus RNA and hepatitis C virus core antigen.
    Lunel F; Veillon P; Fouchard-Hubert I; Loustaud-Ratti V; Abergel A; Silvain C; Rifflet H; Blanchi A; Causse X; Bacq Y; Payan C;
    J Hepatol; 2003 Nov; 39(5):826-33. PubMed ID: 14568267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ribavirin and amantadine on early hepatitis C virus RNA rebound and clearance in serum during daily high-dose interferon.
    Lake-Bakaar G; Ruffini L; Kuzmic P
    Dig Dis Sci; 2003 Jan; 48(1):126-39. PubMed ID: 12645800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of ribavirin on dynamics of hepatitis C viremia in interferon alpha-treated patiens with response or no response].
    Berg T; Kaul T; Naumann U; Wiedenmann B; Hopf U
    Z Gastroenterol; 2000 Nov; 38(11):881-6. PubMed ID: 11132533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: a preliminary report.
    Nyberg L; Albrecht J; Glue P; Gianelli G; Zambas D; Elliot M; Conrad A; McHutchison J
    J Clin Gastroenterol; 1999 Jun; 28(4):313-6. PubMed ID: 10372927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report.
    Zylberberg H; Benhamou Y; Lagneaux JL; Landau A; Chaix ML; Fontaine H; Bochet M; Poynard T; Katlama C; Pialoux G; Bréchot C; Pol S
    Gut; 2000 Nov; 47(5):694-7. PubMed ID: 11034587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HCV clearance patterns in saliva and serum of patients with chronic HCV infection under interferon plus ribavirin therapy.
    Diz Dios P; Castro A; Rodríguez I; Reforma NG; Castro M; Eirea M; Hermida M
    J Oral Pathol Med; 2005 May; 34(5):308-11. PubMed ID: 15817075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C virus free-virion and immune-complex dynamics during interferon therapy with and without ribavirin in genotype-1b chronic hepatitis C patients.
    Fujita N; Kaito M; Tanaka H; Horiike S; Urawa N; Sugimoto R; Konishi M; Watanabe S; Adachi Y
    J Viral Hepat; 2006 Mar; 13(3):190-8. PubMed ID: 16475995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load.
    Tsubota A; Akuta N; Suzuki F; Suzuki Y; Someya T; Kobayashi M; Arase Y; Saitoh S; Ikeda K; Kumada H
    Intervirology; 2002; 45(1):33-42. PubMed ID: 11937769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.
    Bell H; Hellum K; Harthug S; Myrvang B; Ritland S; Maeland A; von der Lippe B; Bjøro K; Skaug K; Gutigard BG; Raknerud N; Simmonds P
    Scand J Gastroenterol; 1999 Feb; 34(2):194-8. PubMed ID: 10192200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of pegylated interferon alpha-2a and ribavirin treatment in chronic hepatitis C patients depends on various baseline parameters and early viral kinetics].
    Husa P; Slesinger P; Stroblová H; Svobodník A; Husová L
    Klin Mikrobiol Infekc Lek; 2008 Apr; 14(2):67-73. PubMed ID: 18756436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early hepatitis C virus changes and sustained response in patients with chronic hepatitis C treated with peginterferon alpha-2b and ribavirin.
    Gallegos-Orozco JF; Loaeza-del Castillo A; Fuentes AP; García-Sandoval M; Soto L; Rodríguez R; Gutiérrez-Ruíz MC; Gutiérrez-Reyes G; Bonder A; Olivera MA; Kershenobich D
    Liver Int; 2005 Feb; 25(1):91-5. PubMed ID: 15698404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.